<DOC>
	<DOCNO>NCT00568347</DOCNO>
	<brief_summary>To evaluate role inhaled corticosteroid suppress nitric oxide gas exchange stable patient moderate-to-severe COPD current non-smokers oral corticosteroid .</brief_summary>
	<brief_title>Evaluation Inhaled Corticosteroids Exhaled Nitric Oxide Gas Exchange</brief_title>
	<detailed_description>Stable , non-smoking COPD patient oral corticosteroid randomize single blind study evaluate nitric oxide gas exchange baseline , subsequent effect fluticasone 100mcg/salmeterol 50mcg bid , fluticasone 250mcg/salmeterol 50mcg bid . Primary end point include measurement nitric oxide vary expiratory flow rate calculate bronchial , small airway/alveolar nitric oxide . Secondary end point evaluate lung function . Exhaled nitric oxide production presumably reflect endogenous inflammation . Normal healthy , non-smoking control use comparison , exhale nitric oxide measure 3 week low dose inhlaed corticosteroid .</detailed_description>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Clinical diagnosis copd Current nonsmoker Not oral corticosteroid Must able use Advair discus salmeterol discus Pregnancy Current smoker On corticosteroid Clinically unstable</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>chronic airflow obstruction</keyword>
</DOC>